Announcement of Availability for Botensilimab
June 25, 2024
The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab, a next-generation anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, which is being developed by CTEP as an anticancer agent in collaboration with Agenus Inc. CTEP will also consider requests to supply botensilimab for nonclinical studies. All clinical and nonclinical researchers interested in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm). All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.
If you are a DFHCC Investigator interested in submitting an LOI using Botensilimab through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)
Questions may be addressed to Dr. Cheryl Pickett (cheryl.pickett@nih.gov) Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu).
For more information please see the Related Links Below: